New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
08:20 EDTRDHLRedHill Biopharma announces commencement of bioavailability study of RHB-103
RedHill Biopharma together with IntelGenx announced the commencement of a comparative bioavailability clinical study comparing RHB-103 to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application for RHB-103, a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. Results of the bioavailability study are anticipated by June.
News For RDHL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
08:12 EDTRDHLRedHill Biopharma, IntelGenx submit EU MAA application for RIZAPORT
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use